Furthermore, immune responses of CD4+ T cells against tumor-associated antigens were observed following oxaliplatin treatment in chemotherapy-naïve patients with mCRC (colorectal cancer) (Galaine et al., 2019). This evidence concerns the gene CD4 and neoplasm.